Fort Collins biomedical startup acquires Neocart assets
FORT COLLINS — A Fort Collins startup that aims to develop technologies that address the continuum of health care for specific types of human disease has added a new technology that it hopes will form the basis of its platform.
Medavate Corp., based at 3003 E. Harmony Road, Suite 410A, signed an agreement May 8 to acquire “substantially all” of the assets related to the Neocart regenerative-knee treatment from Histogenics Corp. (Nasdaq: HSGX), a troubled Boston-based company that is being absorbed into Ocugen Inc., based in Malvern, Pa.
Medavate will pay $6.5 million for the technology, conditional on approval by Histogenics shareholders…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Enlitic Inc. (ASX:ENL), a health-care data analytics firm with operations in Fort Collins and Australia,…
-
Woodward Inc. (Nasdaq: WWD), a Fort Collins company that designs, manufactures and services energy-conversion and…
-
Anthony’s Pizza & Pasta is opening a restaurant on Sept. 13 in Fort Collins.
-
Big O Tires Fort Collins has donated $5,000 to Coats & Boots, a fundraiser sponsored…
